혈우병 고항체 반응군 환자에 대한 Activated Prothrombin Complex Concentrate (aPCC) 유지요법 = Maintenance Therapy with Activated Prothrombin Complex Concentrate (aPCC) for Hemophilia Patients with High Levels of Responding Inhibitors

다국어 초록 (Multilingual Abstract)

Background: Eleven percent of severe hemophilia A patients and 5% of severe hemophilia B patients may develop inhibitors. We have conducted aPCC-based maintenance therapy for hemophilia patients with high levels of responding inhibitors and we analyzed the efficacy, safety, the factor consumption and the expense of this treatment, as compared to on-demand therapy.
Methods: Eleven hemophilia patients with high levels of responding inhibitors were eligible for the study. We tried to evaluate the longitudinal bleeding episodes, the inhibitor titers, the X-ray findings, the adverse events and the factor consumption between on-demand therapy and maintenance therapy. The bypassing agent in this study was aPCC having a longer half-life. The dosage was 30∼50 U/kg, 3 times a week.
Results: The mean follow-up period was 6.8 months for on-demand therapy and 10.6 months for maintenance therapy. The mean dosage of aPCC was 45.2 U/kg. The episodes of hemarthrosis decreased by 61.4% (P=0.003) and other significant bleedings decreased by 45.2% (P=0.109). The inhibitor titers decreased in 7 patients and these increased in 4 patients, but anamnesis took place in only 1 patient. Radiologically, 2 patients improved, 1 patient got worse and 7 patients were stable. Neither adverse signs nor symptoms were noticed. The mean factor consumption changed from 55.8×103 U for aPCC and 48.6 mg for rFVIIa on-demand therapy to 216×103 U for aPCC and 4.8 mg rFVIIa for maintenance therapy. Maintenance therapy cost 67% more than on-demand therapy monthly (P=0.041).
Conclusion: aPCC-based maintenance therapy for hemophilia patients with high responding inhibitors cost 67% more than on-demand therapy, but it reduced by 61.4% the episodes of hemarthrosis and 45.2% of the other significant bleedings. aPCC-based maintenance therapy can very effectively reduce the bleeding episodes of hemophilia patients with high levels of responding inhibitors.

참고문헌 (Reference)

1 Leissinger CA, "Use of prothrombin complex concentrates and activated prothrombin complex concentrates as prophylactic therapy in haemophilia patients with inhibitors" 5 (5): 25-32, 1999

2 김대현, "Thromboelastography를 이용한 혈액응고 기능 평가에 측정 시간과 혈액의 온도가 미치는 영향" 대한마취과학회 42 (42): 306-311, 2002

3 Morfini M, "The design and analysis of half-life and recovery studies for factor VIII and factor IX. Factor VIII/Factor IX scientific and standardization committee of the international society for thrombosis and haemostasis" 66 : 384-386, 1991

4 Valentino LA, "The benefits of prophylactic treatment with APCC in patients with haemophilia and high-titre inhibitors: a retrospective case series" 15 : 733-742, 2009

5 Konkle BA, "Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis on hemophilia patients with inhibitors" 5 : 1904-1913, 2007

6 Leissinger CA, "Prophylactic treatment with activated prothrombin complex concentrate (FEIBA) reduces the frequency of bleeding episodes in paediatric patients with haemophilia A and inhibitors" 13 : 249-255, 2007

7 Siegmund B, "Prophylactic treatment with FEIBA of a haemophilia A patient with inhibitor: what are the costs, what are the benefits?" 11 : 638-641, 2005

8 Morfini M, "Prophylactic treatment of haemophilia patients with inhibitors: clinical experience with recombinant factor VIIa in European Hemophilia Centres" 13 : 502-507, 2007

9 Villar A, "Pharmacokinetics of activated recombinant coagulation factor VII (NovoSeven) in children vs. adults with haemophilia A" 10 : 352-359, 2004

10 Negrier C, "Multicenter retrospective study on the utilization of FEIBA in France in patients with factor VIII and factor IX inhibitors. French FEIBA Study Group. in: Factor Eight Bypassing Activity" 77 : 1113-1119, 1997

11 Váradi K, "Monitoring the bioavailability of FEIBA with a thrombin generation assay" 1 : 2374-2380, 2003

12 Hilgartner MW, "Long-term FEIBA prophylaxis does not prevent progression of existing joint disease" 9 : 261-268, 2003

13 Arnold WD, "Hemophilic arthroapthy. in: Current concepts of pathogenesis and management" 59 : 287-305, 1977

14 Barrowcliffe TW, "Factor VIII inhibitor bypassing activity: a suggested mechanism of action" 21 : 181-186, 1981

15 Luu H, "FEIBA safety profile in multiple modes of clinical and home-therapy application" 10 (10): 10-16, 2004

16 Cheng S, "FEIBA prophylaxis in hemophila A patients with inhibitors decreases bleeding episodes, improves joint function and enhance quality of life" 12 (12): 371-, 2006

17 Jimenez-Yuste V, "Experiences in the prevention of arthropathy in haemophilia patients with inhibitors" 14 (14): 28-65, 2008

18 Ewenstein B, "Evaluation of FEIBA for prophylaxis in patients with inhibitors" 10 (10): 10-, 2004

19 Lambert T, "Can long-term prophylaxis with APCC improve the bleeding rate and quality of life of frequently bleeding haemophiliacs with inhibitors?" 12 (12): 399-, 2006

20 Yoshioka A, "Anamnestic response following infusion of prothrombin complex concentrates (PCC) and activated prothrombin complex concentrates (aPCC) in haemophilia A patients with inhibitors" 2 (2): 51-58, 1991

21 Ewing NP, "Anamnesis inpatients with hemophilia and inhibitors who receive activated prothrombin complex concentrates for prophylaxis" 5 (5): 158-, 2007

22 Dimichele D, "A retrospective postlicensure survey of FEIBA efficacy and safety" 12 : 352-362, 2006